Loading…
Japanese pharma focused on infectious disease drugs (antivirals, antibiotics) and pain/CNS treatments.
Japanese pharma focused on infectious disease drugs (antivirals, antibiotics) and pain/CNS treatments.
Earns a large part of its income as royalties and dividends from ViiV Healthcare, the HIV drug company in which it holds a minority stake alongside GSK and Pfizer, so a key profit stream does not depend on its own sales force. Its own antivirals and antibiotics are sold to hospitals and, for the COVID drug, partly through government purchases.
Moat: narrow (IP / patents, process know-how). Deep expertise in antivirals/antibiotics plus an HIV royalty stream via a ViiV Healthcare stake.
Headquarters: Osaka, Japan · Founded: 1878 · Employees: 6,223
Size Shionogi & (4507.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $16.6B, the 91st largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥2,982 on 6 Nov 2026.
Performance Over six months the shares fell 6.0%, against +4.0% for the median peer and +1.8% for the Japan market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 45.7% over the last twelve months (peer median +18.9%); the operating margin is 28.7% (peer median 20.8%).
Valuation It trades at 10.9× forward earnings against a peer median of 29.8× (3rd cheapest of 20).
Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -12 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.2 points above its cost of capital (5.0% WACC).
Next results Next results expected around 5 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥637B | ¥500B | ¥438B | ¥435B | ¥427B |
| Revenue growth | — | +14% | +1% | +2% | — |
| Gross profit | ¥485B | ¥405B | ¥365B | ¥369B | ¥357B |
| EBITDA | ¥242B | ¥188B | ¥181B | ¥190B | ¥178B |
| Net income | ¥241B | ¥205B | ¥170B | ¥162B | ¥185B |
| Free cash flow | ¥246B | ¥199B | ¥178B | ¥142B | ¥166B |
| Capital expenditure | ¥38.0B | ¥31.3B | ¥52.1B | ¥28.3B | ¥37.2B |
| Total debt | ¥683B | ¥684B | ¥21.9B | ¥11.6B | ¥9.41B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shionogi & 4507.T | $16.6B | -6% | +46% | 29% | 10.9× | -0.7% |
| Takeda Pharmaceutical 4502.T | $66.4B | +24% | +6% | 18% | 42.1× | 3.0% |
| Daiichi Sankyo 4568.T | $31.9B | +7% | +17% | 13% | 18.6× | 7.2% |
| Pfizer PFE | $168B | +14% | +1% | 26% | 10.4× | -4.3% |
| GSK GSK.L | $102B | 0% | +4% | 25% | 10.6× | -0.1% |
| Merck & MRK | $362B | +33% | +5% | 18% | 17.4× | 4.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4507.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +7.9% | +8.0% | 11th highest of 21 |
| 6-month return | -6.0% | +4.0% | 2nd lowest of 21 |
| Distance from 52-week high | -20.7% | -9.2% | 7th lowest of 21 |
| Revenue growth (TTM) | +45.7% | +18.9% | 5th highest of 21 |
| Operating margin | 28.7% | 20.8% | 8th highest of 21 |
| Forward P/E | 10.9× | 29.8× | 3rd cheapest of 20 |
| Growth the price implies (Req g, 7 yrs) | -0.7% | 6.8% | 7th least demanding of 19 |
| Growth delivered (Del g) | +11.0% | +12.6% | 6th lowest of 19 |
| Hurdle (Req g minus delivered) | -11.6 pp | -12.5 pp | 10th least demanding of 19 |
| ROIC minus cost of capital | +1.2 pp | +7.2 pp | 7th lowest of 21 |
| EV / EBITDA | 12.1× | 18.2× | 4th cheapest of 16 |
| Net debt / EBITDA | 1.3× | -0.1× | 5th most indebted of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shionogi & 4507.T | Japan | $16.6B | -6% | +46% | 29% | 10.9× | -0.7% | +11.0% |
| Sichuan Biokin Pharmaceutical 688506.SS | China | $16.4B | -3% | +14% | -43% | n/a | n/a | n/a |
| Exelixis EXEL | United States | $17.0B | +44% | +9% | 40% | 18.2× | -3.7% | +18.6% |
| Orion ORNAV.HE | Finland | $16.1B | +51% | +34% | 38% | 23.5× | -6.3% | +11.7% |
| Ascendis Pharma A/S ASND | United States | $16.0B | +8% | +128% | 10% | 40.8× | 36.4% | +152.4% |
| PharmaEssentia 6446.TW | Taiwan | $15.8B | +118% | +64% | 38% | 39.2× | 29.3% | +94.8% |
| Swedish Orphan Biovitrum SOBI.ST | Sweden | $17.6B | +13% | +15% | 30% | 25.5× | -1.1% | +13.1% |
| Jazz Pharmaceuticals Public JAZZ | United States | $15.1B | +4% | +13% | 25% | 8.9× | -3.9% | +12.5% |
| Ipsen IPN.PA | France | $14.7B | -4% | +14% | 30% | 10.9× | -7.3% | +7.2% |
| Yunnan Baiyao 000538.SZ | China | $14.7B | +4% | +5% | 11% | 18.0× | -0.5% | +4.7% |
| Torrent Pharmaceuticals TORNTPHARM.NS | India | $19.1B | +9% | +42% | 22% | 72.2× | 37.9% | +11.3% |
| Innovent Biologics 1801.HK | Hong Kong | $19.2B | -5% | +43% | 17% | 53.3× | 11.7% | +26.8% |
| Sichuan Kelun-Biotech Biopharmaceutical 6990.HK | Hong Kong | $13.9B | 0% | +44% | -38% | 1,255.9× | 56.2% | +33.7% |
| Laurus Labs LAURUSLABS.NS | India | $13.3B | +94% | +23% | 24% | 77.0× | 50.9% | +7.3% |
| Alnylam Pharmaceuticals ALNY | United States | $20.9B | -47% | +56% | 20% | 22.2× | 0.9% | +49.8% |
| Sbp 1177.HK | Hong Kong | $12.7B | +4% | +15% | 30% | 18.3× | -5.4% | +5.4% |
| Zydus Lifesciences ZYDUSLIFE.NS | India | $12.7B | +27% | +24% | 17% | 29.8× | n/a | n/a |
| Sigma Healthcare SIG.AX | Australia | $22.4B | -1% | +209% | 9% | 37.1× | 28.2% | +26.1% |
| Recordati REC.MI | Italy | $12.3B | +3% | +9% | 30% | 16.7× | 1.9% | +12.6% |
| Zhangzhou Pientzehuang Pharmaceutical 600436.SS | China | $12.3B | -5% | -19% | 19% | 42.1× | 25.8% | +6.8% |
| Dr. Reddy's Laboratories DRREDDY.NS | India | $12.1B | +5% | -4% | 9% | 31.8× | 30.1% | +12.1% |